Dafné Moreno-Lorenzana, Rocío Juárez-Velázquez, Adriana Reyes-León, Daniel Martínez-Anaya, Luis Juárez-Villegas, Martha Zapata Tarrés, Norma López Santiago, Patricia Pérez-Vera
{"title":"儿童血液恶性肿瘤(B 细胞急性淋巴细胞白血病除外)中的 CRLF2 和 IKZF1 异常。","authors":"Dafné Moreno-Lorenzana, Rocío Juárez-Velázquez, Adriana Reyes-León, Daniel Martínez-Anaya, Luis Juárez-Villegas, Martha Zapata Tarrés, Norma López Santiago, Patricia Pérez-Vera","doi":"10.1080/10428194.2024.2378817","DOIUrl":null,"url":null,"abstract":"<p><p>Rearrangements and overexpression of <i>CRLF2</i> are hallmarks of poor outcomes in <i>BCR::ABL1</i>-like B-ALL, and <i>CRLF2</i> overexpression is a high-risk marker in T-ALL. However, <i>CRLF2</i> alterations in pediatric hematologic malignancies other than B-ALL have not been reported. In this study, we analyzed the <i>CRLF2</i> overexpression, rearrangements (<i>P2RY8::CRLF2</i> and <i>IGH::CRLF2</i>), activation (pSTAT5 and pERK), and the expression of dominant-negative <i>IKZF1</i> isoforms (Ik6 and Ik8), implied in <i>CRLF2</i> dysregulation, in 16 pediatric patients (AML, <i>n</i> = 9; T-ALL, <i>n</i> = 3; LBL, <i>n</i> = 2; HL, <i>n</i> = 1; cytopenia, <i>n</i> = 1). A high frequency of <i>CRLF2</i> rearrangements and overexpression was found in the 16 patients: 28.6% (4/14) showed <i>CRLF2</i> overexpression, 93.8% (15/16) were positive for CRLF2 total protein (cell-surface and/or cytoplasmic), while 62.5% (10/16) were positive for <i>P2RY8::CRLF2</i> and 12.6% (2/16) for <i>IGH::CRLF2</i>. In addition, 43.8% (7/16) expressed Ik6 and Ik8 isoforms. However, only a few patients were positive for the surrogate markers pSTAT5 (14.3%; 2/14) and pERK (21.4%; 3/14).</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1853-1863"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>CRLF2</i> and <i>IKZF1</i> abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.\",\"authors\":\"Dafné Moreno-Lorenzana, Rocío Juárez-Velázquez, Adriana Reyes-León, Daniel Martínez-Anaya, Luis Juárez-Villegas, Martha Zapata Tarrés, Norma López Santiago, Patricia Pérez-Vera\",\"doi\":\"10.1080/10428194.2024.2378817\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rearrangements and overexpression of <i>CRLF2</i> are hallmarks of poor outcomes in <i>BCR::ABL1</i>-like B-ALL, and <i>CRLF2</i> overexpression is a high-risk marker in T-ALL. However, <i>CRLF2</i> alterations in pediatric hematologic malignancies other than B-ALL have not been reported. In this study, we analyzed the <i>CRLF2</i> overexpression, rearrangements (<i>P2RY8::CRLF2</i> and <i>IGH::CRLF2</i>), activation (pSTAT5 and pERK), and the expression of dominant-negative <i>IKZF1</i> isoforms (Ik6 and Ik8), implied in <i>CRLF2</i> dysregulation, in 16 pediatric patients (AML, <i>n</i> = 9; T-ALL, <i>n</i> = 3; LBL, <i>n</i> = 2; HL, <i>n</i> = 1; cytopenia, <i>n</i> = 1). A high frequency of <i>CRLF2</i> rearrangements and overexpression was found in the 16 patients: 28.6% (4/14) showed <i>CRLF2</i> overexpression, 93.8% (15/16) were positive for CRLF2 total protein (cell-surface and/or cytoplasmic), while 62.5% (10/16) were positive for <i>P2RY8::CRLF2</i> and 12.6% (2/16) for <i>IGH::CRLF2</i>. In addition, 43.8% (7/16) expressed Ik6 and Ik8 isoforms. However, only a few patients were positive for the surrogate markers pSTAT5 (14.3%; 2/14) and pERK (21.4%; 3/14).</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"1853-1863\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2024.2378817\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2378817","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
Rearrangements and overexpression of CRLF2 are hallmarks of poor outcomes in BCR::ABL1-like B-ALL, and CRLF2 overexpression is a high-risk marker in T-ALL. However, CRLF2 alterations in pediatric hematologic malignancies other than B-ALL have not been reported. In this study, we analyzed the CRLF2 overexpression, rearrangements (P2RY8::CRLF2 and IGH::CRLF2), activation (pSTAT5 and pERK), and the expression of dominant-negative IKZF1 isoforms (Ik6 and Ik8), implied in CRLF2 dysregulation, in 16 pediatric patients (AML, n = 9; T-ALL, n = 3; LBL, n = 2; HL, n = 1; cytopenia, n = 1). A high frequency of CRLF2 rearrangements and overexpression was found in the 16 patients: 28.6% (4/14) showed CRLF2 overexpression, 93.8% (15/16) were positive for CRLF2 total protein (cell-surface and/or cytoplasmic), while 62.5% (10/16) were positive for P2RY8::CRLF2 and 12.6% (2/16) for IGH::CRLF2. In addition, 43.8% (7/16) expressed Ik6 and Ik8 isoforms. However, only a few patients were positive for the surrogate markers pSTAT5 (14.3%; 2/14) and pERK (21.4%; 3/14).
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor